|
1
|
Parikh SA, Rabe KG, Kay NE, Call TG, Ding
W, Schwager SM, Bowen DA, Conte M, Jelinek DF, Slager SL and
Shanafelt TD: Chronic lymphocytic leukemia in young (≤55 years)
patients: A comprehensive analysis of prognostic factors and
outcomes. Haematologica. 99:140–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shanafelt TD, Rabe KG, Kay NE, Zent CS,
Jelinek DF, Reinalda MS, Schwager SM, Bowen DA, Slager SL, Hanson
CA and Call TG: Age at diagnosis and the utility of prognostic
testing in patients with chronic lymphocytic leukemia. Cancer.
116:4777–4787. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ghia P and Hallek M: Management of chronic
lymphocytic leukemia. Haematologica. 99:965–972. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shahjahani M, Mohammadiasl J, Noroozi F,
Seghatoleslami M, Shahrabi S, Saba F and Saki N: Molecular basis of
chronic lymphocytic leukemia diagnosis and prognosis. Cell Oncol
(Dordr). 38:93–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Puente XS, Pinyol M, Quesada V, Conde L,
Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz
M, et al: Whole-genome sequencing identifies recurrent mutations in
chronic lymphocytic leukaemia. Nature. 475:101–105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gianfelici V: Activation of the NOTCH1
pathway in chronic lymphocytic leukemia. Haematologica. 97:328–330.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sportoletti P, Baldoni S, Del Papa B,
Aureli P, Dorillo E, Ruggeri L, Plebani S, Amico V, Di Tommaso A,
Rosati E, et al: A revised NOTCH1 mutation frequency still impacts
survival while the allele burden predicts early progression in
chronic lymphocytic leukemia. Leukemia. 28:436–439. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Landau DA and Wu CJ: Chronic lymphocytic
leukemia: Molecular heterogeneity revealed by high-throughput
genomics. Genome Med. 5:472013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wan Y and Wu CJ: SF3B1 mutations in
chronic lymphocytic leukemia. Blood. 121:4627–4634. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong HJ, Fang C, Fan L, Zhu DX, Wang DM,
Zhu HY, Zhuang Y, Miao KR, Liu P, Xu W and Li JY: MDM2 promoter
SNP309 is associated with an increased susceptibility to chronic
lymphocytic leukemia and correlates with MDM2 mRNA expression in
Chinese patients with CLL. Int J Cancer. 130:2054–2061. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hua W, Zhang A, Duan P, Zhu J, Zhao Y, He
J and Zhang Z: MDM2 promoter del1518 polymorphism and cancer risk:
Evidence from 22,931 subjects. Onco Targets Ther. 10:3773–3780.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang CZ, Lin J, Qian J, Shao R, Xue D,
Qian W, Xiao GF, Deng ZQ, Yang J, Li Y and Chen XX: Development of
high-resolution melting analysis for the detection of the MYD88
L265P mutation. Clin Biochem. 46:385–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahimi Z, Vaisi-Raygani A, Mozafari H,
Kharrazi H, Rezaei M and Nagel RL: Prevalence of factor V Leiden
(G1691A) and prothrombin (G20210A) among Kurdish population from
Western Iran. J Thromb Thrombolysis. 25:280–283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Argentou N, Vassilopoulos G, Ioannou M,
Germenis A and Speletas M: Rapid detection of MYD88-L265P mutation
by PCR-RFLP in B-cell lymphoproliferative disorders. Leukemia.
28:447–449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jafari Y, Rahimi Z, Vaisi-Raygani A and
Rezaei M: Interaction of eNOS polymorphism with MTHFR variants
increase the risk of diabetic nephropathy and its progression in
type 2 diabetes mellitus patients. Mol Cell Biochem. 353:23–34.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li PP, Feng LL, Chen N, Ge XL, Lv X, Lu K,
Ding M, Yuan D and Wang X: Metadherin contributes to the
pathogenesis of chronic lymphocytic leukemia partially through
Wnt/β-catenin pathway. Med Oncol. 32:4792015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fabbri G, Rasi S, Rossi D, Trifonov V,
Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, et al:
Analysis of the chronic lymphocytic leukemia coding genome: Role of
NOTCH1 mutational activation. J Exp Med. 208:1389–1401. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bilous NI, Abramenko IV, Chumak AA, Dyagil
IS and Martіna ZV: Detection of NOTCH1 c.7541_7542delCT mutation in
chronic lymphocytic leukemia using conventional and real-time
polymerase chain reaction. Exp Oncol. 38:112–116. 2016.PubMed/NCBI
|
|
19
|
Dal Bo M, Pozzo F, Bomben R, Degan M,
Marconi D, Zucchetto A, Rossi D, Pozzato G, Zauli G, Gaidano G, et
al: ARHGDIA, a mutant TP53-associated Rho GDP dissociation
inhibitor, is over-expressed in gene expression profiles of TP53
disrupted chronic lymphocytic leukaemia cells. Br J Haematol.
161:596–599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oscier DG, Rose-Zerilli MJ, Winkelmann N,
Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A,
Gardiner A, Collins A, et al: The clinical significance of NOTCH1
and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 121:468–475.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang L, Lawrence MS, Wan Y, Stojanov P,
Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L,
et al: SF3B1 and other novel cancer genes in chronic lymphocytic
leukemia. N Engl J Med. 365:2497–2506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Quesada V, Conde L, Villamor N, Ordóñez
GR, Jares P, Bassaganyas L, Ramsay AJ, Beà S, Pinyol M,
Martínez-Trillos A, et al: Exome sequencing identifies recurrent
mutations of the splicing factor SF3B1 gene in chronic lymphocytic
leukemia. Nat Genet. 44:47–52. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Te Raa GD, Derks IA, Navrkalova V,
Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H,
Trbusek M, Malcikova J, et al: The impact of SF3B1 mutations in CLL
on the DNA-damage response. Leukemia. 29:1133–1142. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sutton LA, Young E, Baliakas P,
Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J,
Stalika E, Pedersen LB, et al: Different spectra of recurrent gene
mutations in subsets of chronic lymphocytic leukemia harboring
stereotyped B-cell receptors. Haematologica. 101:959–967. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hashemi M, Omrani M, Eskandari-Nasab E,
Hasani SS, Mashhadi MA and Taheri M: A 40-bp insertion/deletion
polymorphism of Murine Double Minute2 (MDM2) increased the risk of
breast cancer in Zahedan, Southeast Iran. Iran Biomed J.
18:245–249. 2014.PubMed/NCBI
|
|
26
|
Insuasti-Beltran G, Gale JM, Wilson CS,
Foucar K and Czuchlewski DR: Significance of MYD88 L265P mutation
status in the subclassification of low-grade B-cell
lymphoma/leukemia. Arch Pathol Lab Med. 139:1035–1041. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baliakas P, Hadzidimitriou A, Sutton LA,
Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J,
Agathangelidis A, Davis Z, et al: Recurrent mutations refine
prognosis in chronic lymphocytic leukemia. Leukemia. 29:329–336.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jeromin S, Weissmann S, Haferlach C,
Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A,
Haferlach T, et al: SF3B1 mutations correlated to cytogenetics and
mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated
CLL patients. Leukemia. 28:108–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rossi D, Rasi S, Spina V, Bruscaggin A,
Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni
F, et al: Integrated mutational and cytogenetic analysis identifies
new prognostic subgroups in chronic lymphocytic leukemia. Blood.
121:1403–1412. 2013. View Article : Google Scholar : PubMed/NCBI
|
